MTOR and sarcoma: Regulatory failures lead to the activation of the phosphatidylinositol-3-kinase (PI3K)–protein kinase B (Akt)–mammalian target of rapamycin (mTOR) pathway which is common in a variety of sarcomas [3,4,5].